genO-hCCR8/hCCL1/hFcγR: tumor growth inhibition + higher CD8/Treg ratio.
📖 www.genoway.com/science/publ...
#CCR8 #Tregs
genO-hCCR8/hCCL1/hFcγR: tumor growth inhibition + higher CD8/Treg ratio.
📖 www.genoway.com/science/publ...
#CCR8 #Tregs
genOway is at Booth #1213.
Whether you’re working on CCR8, IL-18, FcγR or PD-1, our team is ready to talk preclinical models.
Stop by and say hi!
#SITC26 #ImmunoOncology #PreclinicalResearch
genOway is at Booth #1213.
Whether you’re working on CCR8, IL-18, FcγR or PD-1, our team is ready to talk preclinical models.
Stop by and say hi!
#SITC26 #ImmunoOncology #PreclinicalResearch
Just out in Sci Transl Med: CCR8xCD3 T cell-engaging bispecific antibody selectively depletes CCR8-expressing intratumoral regulatory T cells in preclinical mouse models, enabling tumor growth inhibition.
doi.org/10.1126/scitranslmed.aea7127
Just out in Sci Transl Med: CCR8xCD3 T cell-engaging bispecific antibody selectively depletes CCR8-expressing intratumoral regulatory T cells in preclinical mouse models, enabling tumor growth inhibition.
doi.org/10.1126/scitranslmed.aea7127
• AbbVie Beats Again on Skyrizi, Rinvoq and Neuroscience and Signals Bolt-Ons, Not Another Allergan
• KRAS G12D inhibitor INCB161734: from oral tool compound to clinic
#DrugDiscovery #MedChem #Pharma #Biotech
• AbbVie Beats Again on Skyrizi, Rinvoq and Neuroscience and Signals Bolt-Ons, Not Another Allergan
• KRAS G12D inhibitor INCB161734: from oral tool compound to clinic
#DrugDiscovery #MedChem #Pharma #Biotech
On October 28, 2026, Coherus Oncology, Inc. issued a press release announcing the interim clinical data from the TREGCHECKTM development program evaluating tagmokitug, its investigational cytolytic CCR8 antibody, in combination with toripalimab, with or without chemotherapy.
On October 28, 2026, Coherus Oncology, Inc. issued a press release announcing the interim clinical data from the TREGCHECKTM development program evaluating tagmokitug, its investigational cytolytic CCR8 antibody, in combination with toripalimab, with or without chemotherapy.
https://www.stocktitan.net/news/CHRS/coherus-oncology-to-host-webcast-to-disclose-interim-tagmokitug-9ddaogvd3vb8.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/CHRS/coherus-oncology-to-host-webcast-to-disclose-interim-tagmokitug-9ddaogvd3vb8.html?utm_source=stocktitan-bluesky&utm_medium=social
価格: 5053円
https://otokusalesokuhobin.com/amazon-live-sale-b07j1mwlmn-20260829/
価格: 5053円
https://otokusalesokuhobin.com/amazon-live-sale-b07j1mwlmn-20260829/
““Enhanced anti-tumor efficacy via prolonged retention of a novel anti-CCR8/IL2 mutein fusion antibody”, Dr. @elianepiaggio.bsky.social / Egle Therapeutics
👉 www.abstractsonline.com/pp8/#!/20273...
4/4
““Enhanced anti-tumor efficacy via prolonged retention of a novel anti-CCR8/IL2 mutein fusion antibody”, Dr. @elianepiaggio.bsky.social / Egle Therapeutics
👉 www.abstractsonline.com/pp8/#!/20273...
4/4
“Enhanced anti-tumor efficacy via prolonged plasma membrane retention of anti-CCR8/IL2 mutein” – Dr. @elianepiaggio.bsky.social / Egle Therapeutics
👉 www.abstractsonline.com/pp8/#!/20273...
4/4
“Enhanced anti-tumor efficacy via prolonged plasma membrane retention of anti-CCR8/IL2 mutein” – Dr. @elianepiaggio.bsky.social / Egle Therapeutics
👉 www.abstractsonline.com/pp8/#!/20273...
4/4
More importantly, it cannot fund future development of pipeline assets.
If the CCR8 competitive landscape develops and tagmokitug delivers, then #$CHRS can raise more money. But...
More importantly, it cannot fund future development of pipeline assets.
If the CCR8 competitive landscape develops and tagmokitug delivers, then #$CHRS can raise more money. But...
The immuno-oncology drug developer is highly dependent on data readouts for two pipeline assets, CCR8 inhibitor tagmokitug & IL-27 inhibitor casdozokitug.
But a financial risk looms...
🧵👇
The immuno-oncology drug developer is highly dependent on data readouts for two pipeline assets, CCR8 inhibitor tagmokitug & IL-27 inhibitor casdozokitug.
But a financial risk looms...
🧵👇
https://www.biorxiv.org/content/10.1101/2025.05.14.653926v1
https://www.biorxiv.org/content/10.1101/2025.05.14.653926v1
m.youtube.com/watch?v=cCR8...
m.youtube.com/watch?v=cCR8...